Technical analysis (TA) can be a helpful tool for making investment decisions and increasing the profitability of your trades. Even though technical analysis follows predefined rules, the results can ...

For centuries, much of the ocean floor has remained a mystery. Now, thanks to data from NASA’s SWOT satellite, scientists have created one of the most detailed maps ever, revealing hidden underwater ...

The Indian Premier League (IPL) 2025 is almost here. Kolkata Knight Riders are ready to defend their crown while the other nine teams too are ready to challenge the defending champions. (Full ...

CAMBRIDGE, Mass. - Immuneering Corporation (NASDAQ:IMRX), a clinical-stage biotech company with a current market capitalization of $52 million focused on developing therapies for cancer treatment, has ...

Strengths: Mumbai Indians boast of a powerful batting line-up. It is among the few sides whose top and middle-order is almost completely filled with international stars. The side already had T20I ...

Delhi Capitals enter IPL 2025 with Axar Patel as the new captain, featuring star signings like KL Rahul and Mitchell Starc. The team aims to secure their first IPL title with a powerful batting ...

CHICAGO - MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company with a market capitalization of $46.71 million, announced today that the USAN Council has approved ...

Kolkata Knight Riders (KKR) enter the Indian Premier League (IPL) 2025 season as the reigning champions, having pulled off arguably the most dominant campaign in IPL history in 2024. Despite the ...

Kolkata Knight Riders aim to secure their fourth IPL title with Ajinkya Rahane as the new captain. Retaining key players like Sunil Narine and Andre Russell, and adding talents such as Quinton de ...

Mumbai Indians are ready to start their Indian Premier League (IPL) 2025 campaign in search of their sixth title. They have the joint-most number of trophies (5) in the history of IPL. (More ...

Regeneron Pharmaceuticals, Inc. is a well-managed company with a diverse pipeline, but faces the likely decline in revenues from its key drug, Eylea. The loss of Eylea's patent protection has led ...